No description available.

The syntheses of 7-N-chloroacetyllavendamycin methyl ester (55), 7-N-butyryllavendamycin methyl ester (56), 7-N-chloroacetyldemethyllavendamycin octyl ester (57), 7-N-butyryldemethyllavendamycin octyl ester (58), 7-N-chloroacetyldemethyllavendamycin isoamyl ester (59), and 7-N-butyryldemethyllavendamycin isoamyl ester (61) are described. Incorporation of the Pictet-Spengler condensation of 7-chloroacetamido-2-formylquinoline-5,8-dione (62) or 7butyramido-2-formylquinoline-5,8-dione (63) with B - methyltryptophan methyl ester (11), L-tryptophan octyl ester (64), or L-tryptophan isoamyl ester (65) in xylene directly afforded six lavendamycin analogs.The aldehydes 62 and 63 were prepared according to the following general procedure. Nitration of 8-hydroxy-2methylquinoline (66) yielded 8-hydroxy-2-methyl-5,772, and 73 are also included. 1H NMR and IR are provided compounds 67, and 71, and 1H NMR is provided for compound dinitroquinoline (67). Compound 67 was then hydrogenated and acylated with chloroacetic anhydride (or butyric anhydride) to yield 5,7-bis(chloroacet4mido)-8-hydroxy-2-methylquinoline (69) (or 5,7-dibutyramido-8-butyroxy-2 methylquinoline (71)).Compound 69 (and 71) was oxidized by potassium dichromate to give the corresponding 5,8-dione 70 (and 72). Treatment of 70 (and 72) with selenium dioxide in refluxing 1,4-dioxane afforded compound 62 (and 63). It was also noted that 71 would hydrolyze to its 8-hydroxy derivative 73 in hot methanol-water.Compound 64 was prepared through the neutralization of Ltryptophan octyl ester hydrochloride with a 14 % ammonium hydroxide solution followed by extraction. Compound 65 was synthesized via a Fischer esterification of L-tryptophan with isoamyl alcohol saturated with hydrogen chloride. The synthesis of H-methyltryptophan (44) was accomplished with the method of Snyder and Matteson.The structures of the novel compounds 55, 56, 57, 58, 59, 60, 62, 63, 69, 70, 72 and 73 were confirmed through 1H NMR, IR, EIMS, and HRMS. Elemental analyses of 62, 63, 69, 70,for 44. / Department of Chemistry

Membrane type I-matrix metalloproteinase (MT1-MMP), a member of the highly active extracellular matrix (ECM)-degrading matrix metalloproteinases (MMPs), is known to be involved in connective tissue remodelling and embryogenesis, as well as tumour invasion and metastasis. Positioned on the leading edge of the invading cell, its proteolytic activity is enhanced by activation of proMMP-2 in a complex with tissue inhibitor of matrix metalloproteinase-2 (TIMP-2). The aim of this study was to attempt to produce highly specific and immunoinhibitory antibodies against human MT1-MMP and to test whether such antibodies are able to stop invasion by blocking MT1-MMP activity. As various MMP domains are highly conserved across species, and within specific MMP groups, and human cancer cells were to be used in invasion assays, sequence alignment of human MT1-MMP domains was used to identify the most variant and, hence, the optimal laboratory species for antibody production, and the chicken was subsequently selected. A hemopexin-like or collagen-binding domain, together with the catalytic domain (PEXcat), the hemopexin-like domain (PEX) and the propeptide and catalytic domain (PROcat) were selected as target domains for antibody production. Escherichia coli or Pichia pastoris expressed PEXcat and PEX domains, respectively, were obtained collaboratively, and an E. coli expression system was used to express the PROcat domain. Urea and β-mercaptoethanol successfully solubilised PROcat inclusion body protein, and Q- and S-Sepharose ion exchange chromatography, removed majority of the E. coli contaminating proteins, yielding >200 mg/litre expressed PROcat protein. Alum adjuvant and unrenatured soluble PEXcat and PEX proteins, or the less soluble, S-Sepharose purified PROcat protein was used for inoculations of chickens. The PROcat antigen, also injected as a homogenised band in acrylamide, proved to be inferior to S-Sepharose-purified PROcat antigen in alum, as it failed to induce an antibody response. The S-Sepharose-purified PROcat antigen, in alum adjuvant, produced the highest overall response, purified anti-PROcat IgY recognising recombinant forms of MT1-MMP (33 kDa and 50 kDa) and a 63 kDa protein in human blood, concluded to be either latent, soluble MT1-MMP or a non-specific protein. These antibodies, however, failed to detect native human and murine MT1-MMP (43 kDa) in cell line homogenates, suggesting that they possibly did not recognise the zinc-binding site of the catalytic domain in the 43 kDa processed MT1-MMP. In contrast to purified IgY, crude anti-PROcat IgY preparations recognised renatured PROcat MT1-MMP (29 kDa), indicating possible binding and removal of anti-human MT1-MMP antibodies during PEG purification. Despite this, the purified IgY resulted in higher immunoinhibition of the renatured PROcat antigen than the crude IgY. Anti-PEXcat antibodies had low titre, recognising native MT1-MMP in human cell (43 kDa) and mouse macrophage homogenates, but did not recognise the original recombinant PEXcat MT1-MMP antigen or PROcat MT1-MMP, possibly due to levels of loaded antigen being too low for detection in the western blots. Although these antibodies also did not seem to recognise the catalytic domain in the western blots, the high immunoinhibitory effect induced by these antibodies suggested otherwise. The PEX antigen induced the weakest antibody response, antibodies detecting only recombinant MT1-MMP (50 kDa). The anti-PROcat IgY, overall, produced denser labelling of the MCF10A and MCF10A-neoT cell lines, than the anti-PEXcat IgY, and these antibodies preferentially recognised the PRO domain of proMT1-MMP, focused in lamellipodia of the MCF10A cell line. Comparisons between the normal and cancer cell line, the anti-PROcat IgY labelled the MCF10A-neoT cells weaker than they labelled the MCF10A cells and the labelling was spread along the plasma membrane and the base of the cell. The anti-PEXcat IgY, in contrast, showed slightly more labelling of MT1-MMP in the MCF10A-neoT cells, compared to the MCF10A cells, which may promote the invasive phenotype of this cell line. In the fixed tissue, anti-PEXcat labelled all forms of MT1-MMP, as expected. Although similar labelling was observed with the anti-PROcat IgY, these antibodies were most likely recognising proMT1-MMP. Renaturation of Q-Sepharose purified PROcat antigen, using 0.5 mM ZnCl 2 gradient dialysis, produced catalytically active, renatured protein for immunoinhibition assays, although the observed higher Km in this study possibly suggested this procedure was not a successful as a one-step dialysis procedure previously reported. Despite this, immunoinhibition assays revealed a 88%, 70% and 34% inhibition of activity by the anti-PEXcat, PROcat and anti-PEX IgY, respectively, suggesting that the anti-PEXcat IgY would be most useful in invasion inhibition studies. / Thesis (M.Sc.)-University of KwaZulu-Natal, Pietermaritzburg, 2007.

Title page, contents and abstract only. The complete thesis in print form is available from the University of Adelaide Library. / "The objectives of this thesis were to characterise the effects fo AR-targeting agents on the growth of prostate cancer cells and to determine whether combining these agents to target the AR (androgen receptor) at more than one level in the signalling pathway would provide a more complete block of androgen signalling and prostate cancer cell growth." --p. v. / http://proxy.library.adelaide.edu.au/login?url= http://library.adelaide.edu.au/cgi-bin/Pwebrecon.cgi?BBID=1289482 / Thesis (Ph.D.) -- University of Adelaide, School of Medicine,2006

Title page, contents and abstract only. The complete thesis in print form is available from the University of Adelaide Library. / "The objectives of this thesis were to characterise the effects fo AR-targeting agents on the growth of prostate cancer cells and to determine whether combining these agents to target the AR (androgen receptor) at more than one level in the signalling pathway would provide a more complete block of androgen signalling and prostate cancer cell growth." --p. v. / http://proxy.library.adelaide.edu.au/login?url= http://library.adelaide.edu.au/cgi-bin/Pwebrecon.cgi?BBID=1289482 / Thesis (Ph.D.) -- University of Adelaide, School of Medicine,2006

Thesis (Ph. D.)--Biomedical Engineering, Georgia Institute of Technology, 2007. / Committee Chair: Nie, Shuming; Committee Member: Lyon, L. Andrew; Committee Member: McIntire, Larry V.; Committee Member: Murthy, Niren; Committee Member: Prausnitz, Mark R.

No description available.

The 16α-alkylation was achieved via treatment of 3-methoxyestra-1,3,5(10)-trien-17-one-N,N-dimethylhydrazone (118) with n-butyllithium and the appropriate haloalkane to afford exclusive 16α-substitution (119). Subsequent, cupric ion-catalysed hydrolysis, 17-ketone reduction and removal of the 3-hydroxyl protecting group, furnished 16α-methylestra-1,3,5(10)-trien-3,17β-diol (122a) and 16α-ethylestra-1,3,5(10)-trien-3,17β-diol (122b). An alternative sequence to the 16α-ligands, by direct alkylation of the 17-keto-estrone enolate, was also investigated. In this manner 16α-allylestra-1,3,5(10)-trien-3,17β-diol (122c) and 16α-benzylestra-1,3,5,(10)-trien-3,17β-diol (122d) were obtained.

Background: ICG-001, an antagonist of CBP (CREB-binding protein), has been demonstrated to exert anti-tumor activity via the modulation of the Wnt signalling pathway. It has previously been demonstrated that miRNAs play an important role in ICG-001-mediated tumor suppression. In the present study, the role of miRNA-134 and 1-integrin in ICG-001-mediated anti-tumor activity in nasopharyngeal carcinoma (NPC) was examined. Methods: NPC cell lines including C666-1, HONE-1 and HK-1 were used in this study. RT-PCR and Western blot were used to study the expression of miRNA-134 and the protein expression of the target proteins, respectively. Confocal microscopy was used to analyse the subcellular localization of 1-integrin. In the functional studies, in vitro endothelial adhesion assay and in vivo nude mice model were used to evaluate the adhesion and migration of ICG-001-treated NPC cells in animals, respectively. Results: ICG-001 was found to up-regulate the expression of miRNA-134 and down-regulate 1-integrin in NPC cells. The effect was accompanied with the inhibition of the adhesion of NPC cells to lung endothelial cells. In addition, over-expression of miRNA-134 would down-regulate the expression of 1-integrin. Results from 1-integrin 3'UTR Renilla luciferase reporter assay confirmed that 1-integrin is a target of miRNA-134 in NPC cells. In the animal study, the ability of ICG-001-pretreated NPC cells or stable miRNA-134 expressing NPC cells to migrate to the mouse lung was greatly reduced. Conclusion: The CBP antagonist ICG-001 may further be developed as an anti-tumor agent for the treatment of nasopharyngeal carcinoma

Introduction: Breast cancer is the most frequently diagnosed cancer and leading cause of cancer death among women and represents a considerable public health burden in South Africa and other low-middle income countries. Breast cancer management comprises single or combination treatment including surgery, radiotherapy and chemotherapy. Short and long-term complications of these treatments include shoulder morbidities such as pain, decreased range of motion, tightness, weakness, pain, numbness and lymphoedema, and may be present for up to 6 years post-surgery. An understanding of baseline demographic and clinical risk factors can guide rehabilitation and management strategies for high risk patients. Materials and Methods: This study was a cross-sectional analysis of the prevalence of shoulder pain and dysfunction in women attending their post-treatment annual follow up visit for unilateral breast carcinoma. The aim of this study was to quantify the burden of shoulder pain and disability in a tertiary academic hospital in Cape Town, South Africa, and identify potential risk factors for the development of shoulder morbidity. The primary objective of this study was to determine the prevalence of shoulder morbidity and the secondary objective was to evaluate associations between shoulder morbidity and risk factors such as treatment protocol or baseline demographics. Results: The majority of patients were of mixed ancestry, had their left side affected, received ALND and had undergone Modified Radical Mastectomy. The mean age was 60 years with a mean follow-up since surgery of 6 years. Three-quarters of patients reported a presence of pain or disability; 9% experienced severe pain and disability. Multivariable ordinal logistic regression analysis identified race, side, axillary surgery, chemotherapy and age as significant predictors of pain, and chemotherapy a significant predictor of disability. Discussion: The substantial burden of shoulder morbidity in this population represents a significant public health burden. The use of identified clinical and demographic characteristics may guide in the development of survivorship programmes incorporating surveillance and management of these high risk patients.